The role of FGF-2 in smoke-induced emphysema and the therapeutic potential of recombinant FGF-2 in patients with COPD

• DOI: 10.1038/s12276-018-0178-y
• Publication Date: 2018-11-14T09:57:53Z
• Authors: You-Sun Kim; Goohyeon Hong; Doh Hyung Kim; Young Min Kim; Yoon-Keun Kim; Yeon-Mok Oh; Young-Koo Jee
• Keywords: Therapeutic effect

Although the positive effects of recombinant fibroblast growth factor-2 (rFGF-2) in chronic obstructive pulmonary disease (COPD) have been implicated previous studies, knowledge its role COPD remains limited. The mechanism FGF2 a mouse model and therapeutic potential rFGF-2 were investigated COPD. protective evaluated cigarette smoke-exposed or elastase-induced animal models. Inflammation was assessed alveolar cells lung tissues from mice. FGF-2 decreased lungs Intranasal use significantly reduced macrophage-dominant inflammation destruction lungs. In emphysema model, improved regeneration humans, plasma compared with normal subjects (10 subjects, P = 0.037). safety efficacy inhaled examined patients, along changes respiratory symptoms function. A 2-week treatment (n 6) resulted baseline levels (P < 0.05); however, results not significant placebo. function test numerically those placebo, but difference statistically significant. No serious adverse events occurred during rFGF-2. loss production is an important development Inhaling may be new option for patients because decreases exposed to smoke. Studies on protein 'fibroblast factor-2' (FGF-2) suggest that could help treat linked smoking. Researchers South Korea led by Young-Koo Jee at Dankook University, Cheonan, Yeon-Mok Oh University Ulsan, Seoul, studied found mice caused exposure They also uncovered details effect FGF-2, identifying specific cellular structure attributed administered FGF-2. Reduced Initial trials revealed some improvement treated level. Nevertheless, authors their justify further investigation protein's potential.